Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Novartis ag crawled time : 13:15 save search
Excision BioTherapeutics Expands Management Team with Three Key Appointments
Published: 2021-10-12 (Crawled : 13:15) - biospace.com/
SYK | $339.13 -0.85% 0.0% 1M
|
Health Technology
|
| O: 0.47%
H: 0.13%
C: -0.68%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.11%
H: 0.34%
C: -0.33%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
RCKT S | $24.01 -0.74% -0.75% 580K
|
Health Technology
|
| O: 1.3%
H: 0.9%
C: 0.31%
CLLS | $2.59 -3.72% -3.86% 42K
|
Health Technology
|
| O: 1.33%
H: 2.18%
C: 0.0%
iot
Diabetic Macular Edema Market size worth $ 4.87 Billion, Globally, by 2028 at 2.86% CAGR: Verified Market Research®
Published: 2021-10-07 (Crawled : 13:15) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.72%
H: 0.1%
C: 0.1%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.62%
H: 1.0%
C: 0.22%
KOD | $3.865 -12.36% -14.1% 580K
|
Health Technology
|
| O: 0.34%
H: 4.38%
C: 2.23%
research macular diabetic diabetes
BioTheryX Announces Appointments of Three New Members to its Board of Directors
Published: 2021-08-06 (Crawled : 13:15) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.85%
H: 0.15%
C: -0.16%
ALDX 4 | $4.17 -1.88% -1.92% 500K
|
Health Technology
|
| O: 1.04%
H: 1.86%
C: 1.55%
iot
Global Mobile Medical Apps Market to Reach $16.5 Billion by 2026
Published: 2021-07-01 (Crawled : 13:15) - prnewswire.com
ARVL | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -0.06%
H: 1.6%
C: -0.45%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.05%
H: 0.5%
C: 0.39%
MDT | $80.23 0.13% 0.2% 6.9M
|
Health Technology
|
| O: 0.27%
H: 1.39%
C: 1.34%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.35%
H: 1.18%
C: 0.53%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.6%
H: 0.48%
C: 0.21%
BSX | $67.44 -0.93% 0.0% 6.5M
|
Health Technology
|
| O: 0.05%
H: 1.71%
C: 1.36%
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: -0.28%
H: 1.45%
C: 1.34%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.27%
H: 0.36%
C: 0.08%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -0.05%
H: 0.95%
C: 0.73%
mobile
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Published: 2021-06-04 (Crawled : 13:15) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.55%
H: 0.41%
C: 0.0%
therapy cancer trial
Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.55%
H: 0.41%
C: 0.0%
response
Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
Published: 2021-06-02 (Crawled : 13:15) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
trial response
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.